Head to Head Contrast: Rafael (NYSE:RFL) vs. Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Rafael (NYSE:RFL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Rafael has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Earnings & Valuation

This table compares Rafael and Recordati Industria Chimica E Farmaceutica”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920,000.00	72.93	-$30.52 million	($0.79)	-1.63
Recordati Industria Chimica E Farmaceutica	$2.96 billion	3.89	$501.80 million	$2.39	23.38

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Rafael and Recordati Industria Chimica E Farmaceutica, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1	0	0	0	1.00
Recordati Industria Chimica E Farmaceutica	0	1	0	2	3.33

Profitability

This table compares Rafael and Recordati Industria Chimica E Farmaceutica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rafael	-2,846.60%	-37.27%	-31.02%
Recordati Industria Chimica E Farmaceutica	16.92%	34.11%	12.59%

Summary

Recordati Industria Chimica E Farmaceutica beats Rafael on 9 of the 13 factors compared between the two stocks.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.